書籍詳細

第1章 概念・定義と疫学

P.21 掲載の参考文献

• 1) 日本動脈硬化学会 : 動脈硬化性疾患予防ガイドライン2012年版.

• 2) O'Keefe J H Jr, et al : Optimal low-density lipoprotein is 50 to 70 mg/dl. Lower is better and physiologically normal. J Am Coll Cardiol 43 : 2142-2146, 2004.
  pubmed

• 3) Crouse J R 3rd, et al : Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis : the METEOR Trial. JAMA 297 : 1344-1353, 2007.
  pubmed

• 4) 中田佳延, 他 : 関節リウマチ・膠原病患者における脂質異常症の管理. Keynote RA 2 : 49-53, 2014.

• 5) Barter P J, et al : Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 : 2109-2122, 2007.
  pubmed

• 6) Schwartz G G, et al : Effects of dalcetrapib in patients with a recent acute coronary syndrome.N Engl J Med 367 : 2089-2099, 2012.
  pubmed

• 7) Voight B F, et al : Plasma HDL cholesterol and risk of myocardial infarction : a mendelian randomisation study. Lancet 380 : 572-580, 2012.
  pubmed

• 8) Franceschini G, et al : A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an italian family, J Clin Invest 66 : 892-900, 1980.

• 9) Florentin M, et al : Multiple actions of high-density lipoprotein. Curr Opin Cardiol 23 : 370-378, 2008.
  pubmed

P.29 掲載の参考文献

• 1) 市原清志 : 基準範囲, 基準値と臨床判断値. エビデンスに基づく検査診断実践マニュアル(市原清志, 他 編), p7-12. 日本教育研究センター, 大阪, 2011.

• 2) 厚生労働省健康局 : 標準的な健診・保健指導に関するプログラム(確定版) 第2編健診, 別紙5. http://www.mhlw.go.jp/bunya/kenkou/seikatsu/pdf/02b.pdf

• 3) 日本動脈硬化学会 : 本ガイドラインの要約. 動脈硬化性疾患予防ガイドライン 2012年版(日本動脈硬化学会 編集), p13-18. 日本動脈硬化学会, 東京, 2012.

• 4) 日本人間ドック学会・健康保険組合連合会検査基準値及び有用性に関する調査研究小委員会 : 新たな健診の基本検査の基準範囲. 日本人間ドック学会, 東京, 2014.<http://www.ningen-dock.jp/wp/wp-content/uploads/2013/09/%E3%83%97%E3%83%AC%E3%82%B9%E3%83%AA%E3%83%AA%E3%83%BC%E3%82%B9%E7%94%A8PDF%EF%BC%88140409%E5%B7%AE%E3%81%97%E6%9B%BF%E3%81%88%EF%BC%89.pdf>

• 5) NCCLS : How to define and determine reference intervals in the clinical laboratory ; Approved Guideline. NCCLS Document C28-P 12 (2) : 1995.

• 6) 市原清志 : 潜在基準値法による日常検査情報の活用. 臨検49(12) : 1471-1485, 2005.

• 7) Ichihara K, et al : An appraisal of statistical procedures used in derivation of reference intervals. Clin Chem Lab Med 48(11) : 1537-1551, 2010.
  pubmed

• 8) Ichihara K, et al : The Asian project for collaborative derivation of reference intervals : (1) strategy and major results of standardized analyses. Clin Chem Lab Med 51(7) : 1429-1442, 2013.

• 9) Friedewald W T, et al : Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6) : 499-502, 1972.
  pubmed

• 10) Miida T, et al : A multicenter study on the precision and accuracy of homogeneous assays for LDL-cholesterol : Comparison with a beta-quantification method using fresh serum obtained from non-diseased and diseased subjects. Atherosclerosis 225(1) : 208-215, 2012.
  pubmed

• 11) Arca M, et al : Hypercholesterolemia in postmenopausal women. Metabolic defects and response to low-dose lovastatin. JAMA 271(6) : 453-459, 1994.
  pubmed

• 12) Verschuren W M, et al : Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 274(2) : 131-136, 1995.
  pubmed

• 13) Ikeda N, et al : Adult mortality attributable to preventable risk factors for non-communicable diseases and injuries in Japan : a comparative risk assessment. PLoS Med 9(1) : e1001160, 2012. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265534/

• 14) 杉山大典, 他 : 我が国における脂質異常症の疫学. 日臨71(増刊3) : 131-134, 2013.

• 15) Hata Y : Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese adults. J Atheroscler Thromb 9(1) : 1-27, 2002.
  pubmed

• 16) 山下静也 : 高HDLコレステロール血症. 内科103(1) : 77-85, 2009.

第2章 病理・病態生理

P.40 掲載の参考文献

• 1) Kannel W B, et al : Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease ; The Framingham study. Ann Intern Med 61 : 888-899, 1964、

• 2) Brown M S, et al : Familiar hypercholesterolemia : A genetic defect in the low density lipoprotein receptor. N Engl J Med 294 : 1386-1390, 1976.

• 3) Endo A, et al : Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 72 : 323-326, 1976.
  pubmed

• 4) Ridker P M, et al : Rosvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 59 : 2195-2207, 2008

• 5) Virmani R, et al : Lessons from sudden cardiac death : A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20 : 1262-1275, 2000.
  pubmed

• 6) Mendez J, et al : Relation of severity of atherosclerosis to chemical composition of human aorta. Am J Clin Pathol 51 : 113-118, 1965.

• 7) Bottcher C J, et al : Lipid and fatty-acid composition of coronary and cerebral arteries at different stages of atherosclerosis. Lancet i : 1162-1167, 1960.

• 8) Neubauer S : The failing heart-an engine out of fuel. N Engl J Med 356 : 1140-1151, 2007,
  pubmed

• 9) Bing R J, et al : Metabolism of the human heart. II. Studies on fat, ketone, and amino acid metabolism. Am J Med 16 : 504-515, 1954.
  pubmed

• 10) Muoio D M : Metabolism and vascular fatty acid transport. N Engl J Med 363 : 291-293, 2010.
  pubmed

• 11) Hirano K, et al : Triglyceride deposit cardiomy-ovasculopathy. N Engl J Med 359 : 2396-2398, 2008.

• 12) Ikeda Y, et al : A novel type of human spontaneous coronary atherosclerosis with triglyceride deposition. Eur Heart J 35 : 875, 2014.
  pubmed

• 13) Ikeda Y, et al : Coronary triglyceride deposition in contemporary advanced diabetics. Pathol Int 64 : 325-335, 2014.
  pubmed

P.49 掲載の参考文献

• 1) Brown M S, et al : A receptor-mediated pathway for cholesterol homeostasis. Science 232(4746) : 34-47, 1986.
  pubmed

• 2) Bu G : Apolipoprotein E and its receptors in Alzheimer's disease : pathways, pathogenesis and therapy. Nat Rev Neurosci 10 (5) : 333-344, 2009.
  pubmed

• 3) Springer T A : An extracellular beta-propeller module predicted in lipoprotein and scavenger receptors, tyrosine kinases, epidermal growth factor precursor, and extracellular matrix components. J Mol Biol 283(4) : 837-862, 1998.
  pubmed

• 4) Jeon H, et al : Implications for familial hypercholesterolemia from the structure of the LDL receptor YWTD-EGF domain pair. Nat Struct Biol 8(6) : 499-504, 2001.
  pubmed

• 5) Jeon H, et al : Structure and physiologic function of the low-density lipoprotein receptor. Annu Rev Biochem 74 : 535-562, 2005.
  pubmed

• 6) Goldstein J L, et al : The LDL receptor. Arterioscler Thromb Vasc Biol 29(4) : 431-438, 2009.
  pubmed

• 7) Yla-Herttuala S : Expression of lipoprotein receptors and related molecules in atherosclerotic lesions. Curr Opin Lipidol 7(5) : 292-297, 1996.
  pubmed

• 8) Schneider W J, et al : Novel members of the low density lipoprotein receptor superfamily and their potential roles in lipid metabolism, Curr Opin Lipidol 8(5) : 315-319, 1997.
  pubmed

• 9) Hiltunen T P, et al : Expression of LDL receptor, VLDL receptor, LDL receptor-related protein, and scavenger receptor in rabbit atherosclerotic lesions : marked induction of scavenger receptor and VLDL receptor expression during lesion development. Circulation 97(11) : 1079-1086, 1998.
  pubmed

• 10) Kanaki T, et al : Expression of LR11, a mosaic LDL receptor family member, is markedly increased in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 19(11) : 2687-2695, 1999.

• 11) Zhu Y, et al : LR11, an LDL receptor gene family member, is a novel regulator of smooth muscle cell migration. Circ Res 94(6) : 752-758, 2004.
  pubmed

• 12) Bujo H, et al : Modulation of smooth muscle cell migration by members of the low-density lipoprotein receptor family. Arterioscler Thromb Vasc Biol 26(6) : 1246-1252, 2006.
  pubmed

• 13) Canton J, et al : Scavenger receptors in homeostasis and immunity. Nat Rev Immunol 13(9) : 621-634, 2013.
  pubmed

• 14) Shi X, et al : Characterization of residues and sequences of the carbohydrate recognition domain required for cell surface localization and ligand binding of human lectin-like oxidized LDL receptor. J Cell Sci 114(Pt 7) : 1273-1282, 2001.

• 15) Kar N S, et al : Mapping and characterization of the binding site for specific oxidized phospholipids and oxidized low density lipoprotein of scavenger receptor CD36. J Biol Chem 283(13) : 8765-8771, 2008.
  pubmed

• 16) Stephen S L, et al : Scavenger receptors and their potential as therapeutic targets in the treatment of cardiovascular disease. Int J Hypertens 17 : 646929, 2010.

• 17) Rahaman S O, et al : A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab 4(3) : 211-221, 2006.
  pubmed

• 18) Lubrano V, et al : LOX-1 and ROS, inseparable factors in the process of endothelial damage. Free Radic Res 48(8) : 841-848, 2014.
  pubmed

• 19) May P, et al : The LDL receptor-related protein(LRP) family : an old family of proteins with new physiological functions. Ann Med 39(3) : 219-228, 2007.
  pubmed

• 20) Yamayoshi S, et al : Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15(7) : 798-801, 2009.
  pubmed

P.65 掲載の参考文献

• 1) Goldstein J L, et al : Regulation of the mevalonate pathway. Nature 343 : 425-430, 1990.
  pubmed

• 2) Bucher N L R, et al : s-Hydroxy-s-methylglutaryl coenzyme A reductase, cleavage and condensing enzymes in relation to cholesterol formation in rat liver. Biochim Biophys Acta 40 : 491-501, 1960.

• 3) Siperstein M D, et al : Feedback control of mevalonate synthesis by dietary cholesterol. J Biol Chem 241 : 602-609, 1966.
  pubmed

• 4) Brown M S, et al : A receptor-mediated pathway for cholesterol homeostasis. Science 232 : 34-47, 1986.
  pubmed

• 5) Goldstein JL, et al : Familial hypercholesterolemia. In : The Metabolic and Molecular Bases of Inherited Disease (Scriver C R, et al, eds), p1981-2030. McGraw-Hill, Inc, New York, 1995.

• 6) Wang X, et al : Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. II. Purification and characterization. J Biol Chem 268 : 14497-14504, 1993.
  pubmed

• 7) Briggs M R, et al : Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. I. Identification of the protein and delineation of its target nucleotide sequence. J Biol Chem 268 : 14490-14496, 1993.
  pubmed

• 8) Smith J R, et al : Identification of nucleotides responsible for enhancer activity of sterol regulatory element in low density lipoprotein receptorgene. J Biol Chem 265 : 2306-2310, 1990.

• 9) Yokoyama C, et al : SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptorgene. Cell 75 : 187-197, 1993.

• 10) Hua X, et al : SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc Natl Acad Sci USA 90 : 11603-11607, 1993.
  pubmed

• 11) Hua X, et al : Structure of the human gene encoding sterol regulatory element binding protein-1(SREBF1) and localization of SREBF1 and SREBF2 to chromosomes 17p11.2 and 22q13. Genomics 25 : 667-673, 1995.
  pubmed

• 12) Brown M S, et al : The SREBP pathway : regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89 : 331-340, 1997.
  pubmed

• 13) Sakai J, et al : Sterol-regulated release of SREBP-2 from cell membranes requires two sequential cleavages, one within a transmembrane segment. Cell 85 : 1037-1046, 1996.
  pubmed

• 14) Duncan E A, et al : Cleavage site for sterol-regulated protease localized to a leu-Ser bond in the lumenal loop of sterol regulatory element-binding protein-2. J Biol Chem 272 : 12778-12785, 1997.
  pubmed

• 15) Duncan E A, et al : Second-site cleavage in sterol regulatory element-binding protein occurs at transmembrane junction as determined by cysteine panning. J Biol Chem 273 : 17801-17809, 1998.

• 16) Rawlings N D, et al : Evolutionary families of metallopeptidases. Meth Enzymol 248 : 183-228, 1995.

• 17) Rawson R B, et al : Complementation cloning of S2P, a gene encoding a putative metalloproteas required for intramembrane cleavage of SREBPs. Mol Cell 1 : 47-57, 1997.
  pubmed

• 18) Zelenski N G, et al : Membrane topology of S2P, a protein required for intramembranous cleavage of sterol regulatory element-binding proteins. J Biol Chem 274 : 21973-21980, 1999.
  pubmed

• 19) Hua X, et al : Sterol resistance in CHO cells traced to point mutation in SREBP cleavage-activating protein. Cell 87 : 415-426, 1996.

• 20) Sakai J, et al : Identification of complexes between the COOH-terminal domains of sterol regulatory element-binding proteins (SREBPs) and SREBP cleavage-activating protein. J Biol Chem 272 : 20213-20221, 1997.
  pubmed

• 21) Sakai J, et al : Cleavage of sterol regulatory element-binding proteins (SREBPs) at site-1 requires interaction with SREBP cleavage-activating protein. Evidence from in vivo competition studies. J Biol Chem 273 : 5785-5793, 1998.
  pubmed

• 22) Rawson R B, et al : Isolation of cholesterol-requiring mutant Chinese hamster ovary cells with defects in cleavage of sterol regulatory element-binding proteins at site 1. J Biol Chem 273 : 28261-28269, 1998.
  pubmed

• 23) Sakai J, et al : Molecular identification of the sterol-regulated luminal protease that cleaves SREBPs and controls lipid composition of animal cells. Mol Cell 2 : 505-514, 1998.
  pubmed

• 24) Dreyer C, et al : Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68 : 879-887, 1992.
  pubmed

• 25) Kliewer S A, et al : Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91 : 7355-7359, 1994.
  pubmed

• 26) Tanaka T, et al : Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 100 : 15924-15929, 2003.
  pubmed

• 27) Janowski B A, et al : An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383 : 728-731, 1996.
  pubmed

• 28) Fu X, et al : 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem 276 : 38378-38387, 2001.

• 29) Lehmann J M, et al : Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 272 : 3137-3140, 1997.
  pubmed

• 30) Peet D J, et al : Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93 : 693-704, 1998.
  pubmed

• 31) Alberti S, et al : Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J Clin Invest 107 : 565-573, 2001.
  pubmed

• 32) Chen G, et al : Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci USA 101 : 11245-11250, 2004.
  pubmed

• 33) Joseph S B, et al : Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 9 : 213-219, 2003.

• 34) Watanabe M, et al : Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439 : 484-489, 2006.
  pubmed

• 35) Holt J A, et al : Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 17 : 1581-1591, 2003.
  pubmed

• 36) Inagaki T, et al : Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2 : 217-225, 2005.
  pubmed

P.72 掲載の参考文献

• 1) Altmann S W, et al : Niemann-PickC1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303 : 1201-1204, 2004.

• 2) Salen G, et al : Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 109 : 966-971, 2004.
  pubmed

• 3) Chang T Y, et al : Ezetimibe blocks internalization of the NPC1L1/cholesterol complex. Cell Metabolism 7(6) : 469-471, 2008.
  pubmed

• 4) Freeman D J, et al : Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environment factors. Association between the Taq1B RFLP in the CETP gene and smoking and obesity. Arterioscler Thromb 14 : 336-344, 1994.

• 5) Sigurdsson G Jr, et al : Interaction between a polymorphorism of the apo A-1 promoter region and smoking determines plasma levels of HDL and apo A-1. Arterioacler Thromb 12 : 1017-1022, 1992.

• 6) Vohl M C, et al : Contribution of the cholesteryl ester transfer protein gene TaqIB polymorphism to the reduced plasma HDL-cholesterol levels found in abdominal obese men with the features of the insulin resistance syndrome.Int J Obs 23 : 918-925, 1999.

• 7) Gylling H, et al : Cholesterol absorption and lipoprotein metabolism in type 2 diabetes mellitus with and without coronary artery disease. Atherosclerosis 126(2) : 325-332, 1996.
  pubmed

• 8) Buchwald H, et al : Effect of Partial Ileal Bypass Surgery on Mortality and Morbidity from Coronary Heart Disease in Patients with Hypercholesterolemia-Report of the Program on the Surgical Control of the Hyperlipidemias(POSCH). N Eng J Med 323(14) : 946-955, 1990.

• 9) Strandberg T E, et al : Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly : a prospective study. J Am Coll Cardiol 48 : 708-714, 2006.
  pubmed

• 10) Miettinen TA, et al : Cholesterol synthesis and absorption in coronary patients with lipid triad and isolated high LDL cholesterol in a 4S subgroup. Athelosclerosis 168 : 343-349, 2003.

• 11) Sato K, et al : Dietary cholesterol oxidation products accelerate plaque destabilization and rupture associated with monocyte infiltration/activation via MCP-1-CCR2 pathway in mouse brachiocephatic arteries : Therapic effect of ezetimibe. J Atheloscler Thromb 19(11) : 986-998, 2012.

P.77 掲載の参考文献

• 1) Kannel W B, et al : RISK FACTORS IN CORONARY HEART DISEASE. AN EVALUATION OF SEVERAL SERUM LIPIDS AS PREDICTORS OF CORONARY HEART DISEASE ; THE FRAMINGHAM STUDY. Ann Intern Med 61 : 888-899, 1964.
  pubmed

• 2) Glomset J A, et al : Role of plasma lecithin : cholesterol acyltransferase in the metabolism of high density lipoproteins. J Lipid Res 7 : 638-648, 1966.

• 3) Badimon J J, et al : Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 85 : 1234-1241, 1990.

• 4) Tangirala R K, et al : Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 100 : 1816-1822, 1999.
  pubmed

• 5) Wang N, et al : LXR-induced redistribution of ABCG1 to plasma membrane in macrophages enhances cholesterol mass efflux to HDL. Arterioscler Thromb Vasc Biol 26 : 1310-1316, 2006.
  pubmed

• 6) Jian B, et al : Scavenger receptor class B type I as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors.J Biol Chem 273 : 5599-5606, 1998.

• 7) Hara H, et al : Interaction of free apolipoproteins with macrophages. Formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol. J Biol Chem 266 : 3080-3086, 1991.
  pubmed

• 8) Francis G A, et al : Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier Disease. J Clin Invest 96 : 78-87, 1995.
  pubmed

• 9) Acton S, et al : Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271 : 518-520, 1996.

• 10) Ko K W, et al : Triglyceride transfer is required for net cholesteryl ester transfer between lipoproteins in plasma by lipid transfer protein. Evidence for a hetero-exchange transfer mechanism demonstrated by using novel monoclonal antibodies. J Biol Chem 269 : 28206-28213, 1994.
  pubmed

• 11) Nagano M, et al : Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. J Atheroscler Thromb. 11 : 110-121, 2004.
  pubmed

• 12) Hirano K, et al : Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 17 : 1053-1059, 1997.

• 13) Ishigami M, et al : Large and cholesteryl esterrich high-density lipoproteins in cholesteryl ester transfer protein(CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J Biochcm 116 : 257-262, 1994.
  pubmed

• 14) Matsuura F. et al : HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE-and ABCG1-dependent pathway. J Clin Invest 116 : 1435-1442, 2006.

• 15) Barter P J, et al : Cholesteryl ester transfer protein : a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23 : 160-167, 2003.
  pubmed

• 16) Marotti K R. et al : Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 364 : 73-75, 1993.
  pubmed

• 17) Okamoto H, et al : A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406 : 203-207, 2000.
  pubmed

• 18) Barter P J, et al : Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 : 2109-2122, 2007.
  pubmed

• 19) Funder J W : Aldosterone, sodium, and hypertension : lessons from torcetrapib? Hypertension 55 : 221-223, 2010.
  pubmed

• 20) Schwartz G G, et al : Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367 : 2089-2099, 2012.
  pubmed

• 21) Voight B F, et al : Plasma HDL cholesterol and risk of myocardial infarction : a mendelian randomisation study. Lancet 380 : 572-580, 2012.
  pubmed

P.86 掲載の参考文献

• 1) Nohara A, et al : Absence of familial defective apolipoprotein B-100 in Japanese patients with familial hypercholesterolaemia. Lancet 345(8962) : 1438, 1995.
  pubmed

• 2) Harada-Shiba M, et al : Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb 19(12) : 1043-1060, 2012.

• 3) Mabuchi H, et al : Cutoff point separating affected and unaffected familial hypercholesterolemic paticnts validated by LDL-receptor gene mutants. J Atheroscler Thromb 12(1) : 35-40, 2005.

• 4) Harada-Shiba M, et al : Siblings with normal LDL receptor activity and severe hypercholesterolemia. Arterioscler Thromb 12(9) : 1071-1078, 1992.
  pubmed

• 5) Garcia C K, et al : Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 292(5520) : 1394-1398, 2001.

• 6) Tada H, et al : Autosomal recessive hypercholesterolemia : A mild phenotype of familial hypercholesterolemia. Insight from kinetic study using stable isotope and animal study. J Atheroscler Thromb 2014(in press) .

• 7) Tada H, et al : Altered metabolism of low-density lipoprotein and very-low-density lipoprotein remnant in autosomal recessive hypercholesterolemia : results from stable isotope kinetic study in vivo. Circ Cardiovasc Genet 5(1) : 35-41, 2012.
  pubmed

• 8) Jones C, et al : Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia. J Clin Invest 117(1) : 165-174, 2007.
  pubmed

• 9) Tada H, et al : Post-prandial remnant lipoprotein metabolism in autosomal recessive hypercholesterolaemia. Eur J Clin Invest 42(10) : 1094-1099, 2012.
  pubmed

• 10) Abifadel M, et al : Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34(2) : 154-156, 2003.

• 11) Cohen J, et al : Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37(2) : 161-165, 2005.
  pubmed

• 12) Noguchi T. et al : The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis 210(1) : 166-172, 2010.
  pubmed

• 13) Mabuchi H, et al : Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation. Atherosclerosis 236(1) : 54-61, 2014.
  pubmed

• 14) Kawashiri M, et al : Statin therapy improves fractional catabolic rate of LDL without affecting impaired VLDL and VLDL remnant catabolism in homozygous FH patient due to PCSK9 gene mutation : Evidence from kinetic study with stable isotope. Circulation 126 : A13869, 2012.

• 15) Kawashiri M, et al : Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia. Am J Cardiol 109(3) : 364-369, 2012.
  pubmed

• 16) Stein E A, et al : Effect of monoclonal antibody to PCSK9 on LDL cholesgterol. N Engl J Med 366(12) : 1108-1118, 2012.
  pubmed

• 17) Blom D J, et al : A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 370(19) : 1809-1819, 2014.

• 18) Fitzgerald K, et al : Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9(PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers : a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383(9911) : 60-68, 2014.
  pubmed

• 19) Tada H, et al : A novel type of familial hypercholesterolemia : double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene. Atherosclerosis 219(2) : 663-666, 2011.
  pubmed

P.93 掲載の参考文献

• 1) Andersson S W, et al : Intake of dietary plant sterols is inversely related to serum cholesterol concentration in men and women in the EPIC Norfolk population : a cross-sectional study. Eur J Clin Nutr 58(10) : 1378-1385, 2004.
  pubmed

• 2) Wang P, et al : Association of natural intake of dietary plant sterols with carotid intima-media thickness and blood lipids in Chinese adults : a cross-section study. PLoS One 7 (3) : e32736, 2012.
  pubmed

• 3) Maki K C, et al : Lipid effects of a dietary supplement softgel capsule containing plant sterols/stanols in primary hypercholesterolemia. Nutrition 29(1) : 96-100, 2013.
  pubmed

• 4) Lin X, et al : The effects of phytosterols present in natural food matrices on cholesterol metabolism and LDL-cholesterol : a controlled feeding trial. Eur J Clin Nutr 64(12) : 1481-1487, 2010.
  pubmed

• 5) Ottestad I, et al : Phytosterol capsules and serum cholesterol in hypercholesterolemia : a randomized controlled trial. Atherosclerosis 228 (2) : 421-425, 2013.
  pubmed

• 6) Moghadasian M H. et al : Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis : clinical and experimental evidence. Am J Med 107(6) : 588-594, 1999.
  pubmed

• 7) De Smet E, et al : Effects of plant sterols and stanols on intestinal cholesterol metabolism : suggested mechanisms from past to present. Mol Nutr Food Res 56(7) : 1058-1072, 2012.
  pubmed

• 8) 一般社団法人日本動脈硬化学会 : 動脈硬化性疾患予防ガイドライン2012. 2012.

• 9) Gylling H, et al : Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis 232(2) : 346-360, 2014.
  pubmed

• 10) Moghadasian M H, et al : "Tall oil" -derived phytosterols reduce atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 17(1) : 119-126, 1997.
  pubmed

• 11) Moghadasian M H, et al : Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice : possible mechanisms of action. Circulation 99(13) : 1733-1739, 1999.
  pubmed

• 12) Plat J, et al : Plant sterol or stanol esters retard lesion formation in LDL receptor-deficient mice independent of changes in serum plant sterols. J Lipid Res 47(12) : 2762-2771, 2006.

• 13) Bombo R P, et al : Dietary phytosterol does not accumulate in the arterial wall and prevents atherosclerosis of LDLr-KO mice. Atherosclerosis 231(2) : 442-447, 2013.

• 14) de Jongh S, et al : Plant sterols lower LDL cholesterol without improving endothelial function in prepubertal children with familial hypercholesterolaemia. J Inherit Metab Dis 26(4) : 343-351, 2003.
  pubmed

• 15) Raitakari O T. et al : Plant stanol ester consumption and arterial elasticity and endothelial function. Br J Nutr 100(3) : 603-608, 2008.
  pubmed

• 16) Assmann G, et al : Plasma sitosterol elevations are associated with an increased incidence of coronary events in men : results of a nested casecontrol analysis of the Prospective Cardiovascular Munster(PROCAM) study. Nutr Metab Cardiovasc Dis 16(1) : 13-21, 2006.
  pubmed

• 17) Fassbender K, et al : Moderately elevated plant sterol levels are associated with reduced cardiovascular risk-the LASA study. Atherosclerosis 196(1) : 283-288, 2008.
  pubmed

• 18) Pinedo S, et al : Plasma levels of plant sterols and the risk of coronary artery disease : the prospective EPIC-Norfolk Population Study. J Lipid Res 48(1) : 139-144, 2007.
  pubmed

• 19) Bouic P J, et al : Plant sterols and sterolins : a review of their immune-modulating properties. Altern Med Rev 4(3) : 170-177, 1999.
  pubmed

• 20) Kurano M, et al : Plant sterols increased IL-6 and TNF-alpha secretion from macrophages, but to a lesser extent than cholesterol. J Atheroscler Thromb 18(5) : 373-383, 2011.
  pubmed

• 21) Wooten J S, et al : The Influence of an Obesogenic Diet on Oxysterol Metabolism in C57BL/6J Mice. Cholesterol 2014 : 843468, 2014.
  pubmed

• 22) Ghisletti S, et al : Parallel SUMOylation-dependent pathways mediate gene-and signal-specific transrepression by LXRs and PPARgamma. Mol Cell 25(1) : 57-70, 2007.
  pubmed

• 23) Kim S M, et al : 27-hydroxycholesterol induces production of tumor necrosis factor-alpha from macrophages. Biochem Biophys Res Commun 430(2) : 454-459, 2013.
  pubmed

• 24) Buttari B, et al : 7-Oxu-cholesterol potentiates pro-inflammatory signaling in human M1 and M2 macrophages. Biochem Pharmacol 86(1) : 130-137, 2013.

• 25) Gold E S, et al : 25-Hydroxycholesterol acts as an amplifier of inflammatory signaling. Proc Natl Acad Sci USA 111(29) : 10666-10671, 2014.
  pubmed

• 26) Gargiulo S, et al : Plaque oxysterols induce unbalanced up-regulation of matrix metalloproteinase-9 in macrophagic cells through redox-sensitive signaling pathways : Implications regarding the vulnerability of atherosclerotic lesions. Free Radic Biol Med 51(4) : 844-855, 2011.
  pubmed

• 27) Radhakrishnan A, et al : Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi : oxysterols block transport by binding to Insig. Proc Natl Acad Sci USA 104(16) : 6511-6518, 2007.
  pubmed

• 28) Miah S, et al : Expression of Egr1 and p53 in human carotid plaques and apoptosis induced by 7-oxysterol or p53. Exp Toxicol Pathol 65(5) : 677-682, 2013.
  pubmed

• 29) Li W, et al : Lipid accumulation and lysosomal pathways contribute to dysfunction and apoptosis of human endothelial cells caused by 7-oxysterols. Biochem Biophys Res Commun 409(4) : 711-716, 2011.
  pubmed

• 30) Appukuttan A, et al : Oxysterol-induced apoptosis of smooth muscle cells is under the control of a soluble adenylyl cyclase. Cardiovasc Res 99(4) : 734-742, 2013.
  pubmed

• 31) Shentu T P, et al : The role of oxysterols in control of endothelial stiffness. J Lipid Res 53(7) : 1348-1358, 2012.
  pubmed

• 32) Aramaki Y, et al : Biological studies of cholestane-3beta, 5alpha, 6beta-triol and its derivatives. 1. Hypocholesterolemic effects in rabbits, chickens and rats on atherogenic diets. J Atheroscler Res 7(5) : 653-669, 1967.
  pubmed

• 33) Imai H, et al : Angiotoxicity and arteriosclerosis due to contaminants of USP-grade cholesterol. Arch Pathol Lab Med 100(11) : 565-572, 1976.
  pubmed

• 34) Staprans I, et al : Oxidized cholesterol in the diet accelerates the development of aortic atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 18(6) : 977-983, 1998.
  pubmed

• 35) Ando M, et al : Dietary cholesterol-oxidation products accumulate in serum and liver in apolipoprotein E-deficient mice, but do not accelerate atherosclerosis. Br J Nutr 88(4) : 339-345, 2002.

• 36) Meynier A, et al : Effects of dietary oxysterols on coronary arteries in hyperlipidaemic hamsters. Br J Nutr 87(5) : 447-458, 2002.
  pubmed

• 37) Umetani M, et al : The cholesterol metabolite 27-hydroxycholesterol promotes atherosclerosis via proinflammatory processes mediated by estrogen receptor alpha. Cell Metab 20(1) : 172-182, 2014.
  pubmed

• 38) Dyer R G, et al : 7-ketocholesterol, a specific indicator of lipoprotein oxidation, and malondialdehyde in non-insulin dependent diabetes and peripheral vascular disease. Clin Chim Acta 260(1) : 1-13, 1997.
  pubmed

• 39) Salonen J T, et al : Lipoprotein oxidation and progression of carotid atherosclerosis. Circulation 95(4) : 840-845, 1997.
  pubmed

• 40) Zieden B, et al : Increased plasma 7 beta-hydroxycholesterol concentrations in a population with a high risk for cardiovascular disease. Arterioscler Thromb Vasc Biol 19(4) : 967-971, 1999.

• 41) Rimner A, et al : Relevance and mechanism of oxysterol stereospecifity in coronary artery disease. Free Radic Biol Med 38(4) : 535-544, 2005.
  pubmed

P.102 掲載の参考文献

• 1) Moore K J, et al : Macrophages in the pathogenesis of atherosclerosis. Cell 145 : 341-355, 2011.
  pubmed

• 2) Steinberg D, et al : The LDL modification hypothesis of atherogenesis : An update. J Lipid Res50 : S376-S381, 2009.

• 3) Miyazaki T, et al : Calpain and atherosclerosis. J Atheroscler Thromb 20(3) : 228-237, 2013.
  pubmed

• 4) Miyazaki T, et al : m-Calpain induction in vascular endothelial cells on human and mouse atheromas and its role in VE-cadherin disorganization and atherosclerosis. Circulation 124(23) : 2522-2532, 2011.
  pubmed

• 5) Yoshida H, et al : Mechanisms of LDL oxidation. Clin Chim Acta 411 : 1875-1882, 2010.
  pubmed

• 6) Yu X H, et al : Foam cells in atherosclerosis. Clin Chim Acta 424 : 245-252, 2013.
  pubmed

• 7) Maiolino G, et al : The role of oxidized low-density lipoproteins in atherosclerosis : The myths and the facts. Mediators Inflamm 2013 : 714653, 2013.
  pubmed

• 8) Itabe H : Oxidized low-density lipoprotein as a biomarker of in vivo oxidative stress : from atherosclerosis to periodontitis. J Clin Biochem Nutr51(1) : 1-8, 2012.

P.111 掲載の参考文献

• 1) Austin M A, et al : Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260(13) : 1917-1921, 1988.
  pubmed

• 2) McNamara J R, et al : Differences in LDL subspecies involve alterations in lipid composition and conformational changes in apolipoprotein B. J Lipid Res 37(9) : 1924-1935, 1996.
  pubmed

• 3) St-Pierre A C, et al : Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men : 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 25(3) : 553-559, 2005.

• 4) Koba S, et al : Small dense low-density lipoprotein in Japanese men with coronary artery disease. Ann Intern Med 132(9) : 762, 2000.
  pubmed

• 5) Arai H, et al : Small dense low-density lipoproteins cholesterol can predict incident cardiovascular disease in an urban Japanese cohort : the Suita study. J Atheroscler Thromb 20(2) : 195-203, 2013.

• 6) Taskinen M R : Insulin resistance and lipoprotein metabolism. Curr Opin Lipidol 6(3) : 153-160, 1995.
  pubmed

• 7) Okazaki M. et al : Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler Thromb Vasc Biol 25(3) : 578-584, 2005.
  pubmed

• 8) Ito Y, et al : Development of a homogeneous assay for measurement of small dense LDL cholesterol. Clin Chem 57(1) : 57-65, 2011.
  pubmed

• 9) Tsai M Y, et al : New automated assay of small dense low-density lipoprotein cholesterol identifies risk of coronary heart disease : the Multi-ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol 34(1) : 196-201, 2014.
  pubmed

• 10) Hoogeveen R C, et al : Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease : the Atherosclerosis Risk In Communities(ARIC) study. Arterioscler Thromb Vasc Biol 34(5) : 1069-1077, 2014.
  pubmed

• 11) Nishikura T, et al : Elevated small dense low-density lipoprotein cholesterol as a predictor for future cardiovascular events in patients with stable coronary artery disease. J Atheroscler Thromb 21(8) : 755-767, 2014.
  pubmed

第3章 診断

P.118 掲載の参考文献

• 1) Kannel W B, et al : Efficacy of lipid profiles in prediction of coronary disease. Am Heart J 124 : 768-774, 1992.
  pubmed

• 2) Kitamura A, et al : High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation 89 : 2533-2539, 1994.
  pubmed

• 3) 日本動脈硬化学会 編 : 脂質異常症治療ガイド. 2013.

P.125 掲載の参考文献

• 1) Friedewald W T, et al : Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6) : 499-502, 1972.
  pubmed

• 2) Miller W G, et al : Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem 56(6) : 977-986, 2010.
  pubmed

• 3) Nauck M, et al : Quantitative determination of high-, low-, and very-low-density lipoproteins and lipoprotein (a) by agarose gel electrophoresis and enzymatic cholesterol staining. Clin Chem 41(12) : 1761-1767, 1995.

• 4) Hirowatari Y, et al : Measurement of cholesterol of major serum lipoprotein classes by anion-exchange HPLC with perchlorate ion-containing eluent. J Lipid Res 44(7) : 1404-1412, 2003.
  pubmed

• 5) Hata Y, et al : Application of Friedewald's LDL-cholesterol estimation formula to serum lipids in the Japanese population. Jpn Circ J 50 (12) : 1191-1200, 1986.

• 6) Vujovic A, et al : Evaluation of different formulas for LDL-C calculation. Lipids Health Dis 9 : 27, 2010.
  pubmed

• 7) Chen Y, et al : A modified formula for calculating low-density lipoprotein cholesterol values. Lipids Health Dis 9 : 52, 2010.

• 8) Anandaraja S, et al : Low-density lipoprotein cholesterol estimation by a new formula in Indian population. Int J Cardiol 102(1) : 117-120, 2005.
  pubmed

• 9) Martin S S, et al : Comparison of a novel method vs the Friedewald equation for estimating low-densitylipoprotein cholesterol levels from the standard lipid profile. JAMA 310(19) : 2061-2068, 2013.

• 10) Meeusen J W, et al : Validation of a Proposed Novel Equation for Estimating LDL Cholesterol. Clin Chem (in press)

• 11) Oliveira M J, et al : Evaluation of four different equations for calculating LDL-C with eight different direct HDL-C assays. Clin Chim Acta 423 : 135-140, 2013.
  pubmed

• 12) Lipid Research Clinics Program, Manual of Laboratory Operations. DHEW(NIH) Publication No75-628, 1974 (revised 1982) .

• 13) Abell L L, et al : Simplified method for the estimation of total cholesterol in serum, and demonstration of its specificity. J Biol Chem 195(1) : 357-366, 1952.

• 14) Nakamura M, et al : LDL cholesterol performance of beta quantification reference measurement procedures. Clin Chim Acta 431 : 288-293, 2014.
  pubmed

• 15) Miida T, et al : A multicenter study on the precision and accuracy of homogeneous assays for LDL-cholesterol : comparison with a beta-quantification method using fresh serum obtained from non-diseased and diseased subjects. Atherosclerosis 225(1) : 208-215, 2012.
  pubmed

P.134 掲載の参考文献

• 1) Havel R J, et al : The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34 : 1345-1353, 1955.

• 2) Remaley A T, et al : High-density lipoprotein : What is the best way to measure its antiatherogenic potential? Expert Opin Med Diagn 2 : 773-788, 2008.
  pubmed

• 3) Gofman J W, et al : Ischemic heart disease, atherosclerosis, and longevity. Circulation 34 : 679-697, 1966.
  pubmed

• 4) Salonen J T, et al : Hdl, hdl2, and hdl3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern finnish men. Circulation 84 : 129-139, 1991.
  pubmed

• 5) Smuts C M, et al : Free cholesterol concentrations in the high-density lipoprotein subfraction-3 as a risk indicator in patients with angiographically documented coronary artery disease. Coron Artery Dis 5 : 331-338, 1994.
  pubmed

• 6) Martin S S, et al : HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention : The lipoprotein investigators collaborative. Eur Heart J 2014. [Epub ahead of print]

• 7) Superko H R, et al : High-density lipoprotein subclasses and their relationship to cardiovascular disease. J Clinical Lipidol 6 : 496-523, 2012.
  pubmed

• 8) Blanche P J, et al : Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 665 : 408-419, 1981.
  pubmed

• 9) Johansson J, et al : High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb 11 : 174-182, 1991.

• 10) Berneis K K, et al : Metabolic origins and clinical significance of Idl heterogeneity.J Lipid Res 43 : 1363-1379, 2002.
  pubmed

• 11) Asztalos B F, et al : Role of lcat in hdl remodeling : Investigation of lcat deficiency states. J Lipid Res 48 : 592-599, 2007.

• 12) Asztalos B F, et al : High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the framingham offspring study. Arterioscler Thromb Vasc Biol 24 : 2181-2187, 2004.
  pubmed

• 13) Hirano T, et al : A simple and precise method for measuring hdl-cholesterol subfractions by a single precipitation followed by homogenous hdl-cholesterol assay. J Lipid Res 49 : 1130-1136, 2008.
  pubmed

• 14) Maeda S, et al : Associations between small dense ldl, hdl subfractions(hdl2, hdl3) and risk of atherosclerosis in japanese-americans. J Atheroscler Thromb 19 : 444-452, 2012.

• 15) Lounila J, et al : Effects of orientational order and particle size on the nmr line positions of lipoproteins. Phys Rev Lett 72 : 4049-4052, 1994.
  pubmed

• 16) Ikewaki K, et al : Fenofibrate effectively reduces remnants, and small dense ldl, and increases hdl particle number in hypertriglyceridemic men-a nuclear magnetic resonance study. J Atheroscler Thromb 11 : 278-285, 2004.

• 17) Otvos J D, et al : Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the veterans affairs high-density lipoprotein intervention trial. Circulation 113 : 1556-1563, 2006.
  pubmed

• 18) Khera A V, et al : Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364 : 127-135, 2011.
  pubmed

• 19) Li X M, et al : Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 33 : 1696-1705, 2013.
  pubmed

• 20) Patel P J, et al : The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J Am Coll Cardiol 58 : 2068-2075, 2011.
  pubmed

• 21) Aicher B O, et al : Diet-induced weight loss in overweight or obese women and changes in high-density lipoprotein levels and function. Obesity 20 : 2057-2062, 2012.
  pubmed

• 22) Vaisar T, et al : Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of hdl. J Clin Invest 117 : 746-756, 2007.
  pubmed

• 23) Ansell B J, et al : High-density lipoprotein function recent advances. J Am Coll Cardiol 46 : 1792-1798, 2005.
  pubmed

• 24) Besler C, et al : High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects : A potential novel therapeutic target in cardiovascular disease. Curr Pharm Des 16 : 1480-1493, 2010.
  pubmed

第4章 管理・治療

P.143 掲載の参考文献

• 1) Nakamura Y, et al : Fatty acids intakes and serum lipid profiles : NIPPON DATA90 and the national nutrition monitoring. J Epidemiol 20 : S544-548, 2010.
  pubmed

• 2) Keys A, et al : Serum cholesterol response to changes in dietary lipids. Am J Clin Nutr 19 : 175-181, 1966.

• 3) Hegsted D M, et al : Quantitative effects of dietary fat on serum cholesterol in man. Am J Clin Nutr 17 : 281-295, 1965.

• 4) Vega G L, et al : Influence of polyunsaturated fats on composition of plasma lipoproteins and apolipoproteins. J Lipid Res 23 : 811-822, 1982.
  pubmed

• 5) Matheson B, et al : Effect on serum lipids of monounsaturated oil and margarine in the diet of an Antarctic Expedition. Am J Clin Nutr 63 : 933-938, 1996.
  pubmed

• 6) Bhattacharyya A K : Uptake and esterification of plant sterols by rat small intestine. Am J Physiol 240 : G50-55, 1981.
  pubmed

• 7) Vahouny G V, et al : Dietary fibers : V. Binding of bile salts, phospholipids and cholesterol from mixed micelles by bile acid sequestrants and dietary fibers. Lipids 15 : 1012-1018, 1980.
  pubmed

• 8) Gee J M, et al : The influence of guar gum on intestinal cholesterol transport in the rat. Br J Nutr 50 : 215-224, 1983.
  pubmed

• 9) Weintraub M S, et al : Dietary polyunsaturated fats of the w-6 and w-3 series reduce postprandial lipoprotein levels. Chronic and acute effects of fat saturation on postprandial lipoprotein metabolism. J Clin Invest 82 : 1884-1893, 1988.

• 10) Unno T, et al : Effect of tea catechins on postprandial plasma lipid responses in human subjects. Br J Nutr 93 : 543-547, 2005.
  pubmed

• 11) Toyoda-Ono Y, et al : Suppression of postprandial hypertriglyceridemia in rats and mice by oolong tea polymerized polyphenols. Biosci Biotechnol Biochem 71 : 971-976, 2007.
  pubmed

P.149 掲載の参考文献

• 1) Durstine J L, et al : Blood lipid and lipoprotein adaptations to exercise. Sports Med 31(15) : 1033-1062, 2001.
  pubmed

• 2) Kodama S, et al : Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol. Arch Intern Med 167(10) : 999-1008, 2008.

• 3) Katzmarzyk P T, et al : Physical activity for obese individuals : a systematic review of effects on chronic disease risk factors. Obes Rev 13(1) : 95-105, 2012.

• 4) Tambalis K, et al : Responses of blood lipids to aerobic, resistance, and combined aerobic with resistance exercise training : a systematic review of current evidence. Angiology 60(5) : 614-632, 2009.
  pubmed

• 5) Kelley G A, et al : Comparison of aerobic exercise, diet or both on lipids and lipoproteins in adults : a meta-analysis of randomised controlled trials. Clin Nutr 31(2) : 156-167, 2012.
  pubmed

• 6) Follick M J, et al : Contrastig short-and long-term effects of weight loss on lipoprotein levels. Arch Intern Med 144(8) : 1571-1574, 1994.

• 7) Koba S, et al : Physical activity in the Japan population : association with blood lipid levels and effects in reducing cardiovascular and all-cause mortality. J Atheroscler Thromb 18(10) : 833-845, 2011.
  pubmed

• 8) Hayashino Y, et al : Effects of supervised exercise on lipid profiles and blood pressure control in people with type 2 diabetes mellitus : a meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 98(3) : 349-360, 2012.
  pubmed

• 9) Mann S, et al : Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile : review, synthesis and recommendations. Sports Med 44(2) : 211-221, 2014.
  pubmed

P.156 掲載の参考文献

• 1) 日本動脈硬化学会 : 動脈硬化性疾患予防ガイドライン2012年版. 2012.

• 2) Stone N J, et al : 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63(25) : 2889-2934, 2014.

• 3) Cannon C P, et al : Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350(15) : 1495-1504, 2004.
  pubmed

• 4) Downs J R, et al : Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels : results of AFCAPS/TexCAPS. JAMA 279 (20) : 1615-1622, 1998,
  pubmed

• 5) Fager G, et al : Cholesterol reduction and clinical benefit. Are there limits to our expectations? Arterioscler Thromb Vasc Biol 17(12) : 3527-3533, 1997.
  pubmed

• 6) Singh I M, et al : High-density lipoprotein as a therapeutic target : a systematic review.JAMA 298(7) : 786-798, 2007.

• 7) Natsuaki M, et al : Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization, Perspectives from the CREDO-Kyoto registry cohort-2. Circ J 76(6) : 1369-1379, 2012.
  pubmed

• 8) Kohro T, et al : Intensively lowering both low-density lipoprotein cholesterol and blood pressure does not reduce cardiovascular risk in Japanese coronary artery disease patients. Circ J 75(9) : 2062-2070, 2011.

• 9) Hiro T, et al : Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome : a multi-center randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 54(4) : 293-302, 2009.

• 10) Hayward R A, ct al : Narrative review : lack of evidence for recommended low-density lipoprotein treatment targets : a solvable problem. Ann Intern Med 145(7) : 520-530, 2006.

• 11) Nakamura H, et al : Primary prevention of cardiovascular disease with pravastatin in Japan(MEGA Study) : a prospective randomised controlled trial. Lancet 368(9542) : 1155-1163, 2006.
  pubmed

• 12) AIM-HIGH Investigators : Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365(24) : 2255-2267, 2011.
  pubmed

• 13) Barter P J, et al : Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357(21) : 2109-2122, 2007.
  pubmed

• 14) Keene D, et al : Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors : meta-analysis of randomised controlled trials including 117,411 patients. BMJ 349 : g4379, 2014.
  pubmed

• 15) Rohatgi A, et al : HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events. N Engl J Med 2014 [Epub ahead of print].

P.164 掲載の参考文献

• 1) Mabuchi H, et al : Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb 12 : 111-119, 2005.
  pubmed

• 2) Mabuchi H, et al : Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin : a randomized double-blind study. Atherosclerosis 195 : e182-189, 2007.
  pubmed

• 3) Kawashiri M A, et al : Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia : results from a crossover study. Clin Pharmacol Ther 83 : 731-739, 2008.
  pubmed

• 4) Mabuchi H, et al : Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine. N Engl J Med 308 : 609-613, 1983.
  pubmed

• 5) Nicholls S J, et al : Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids(from VOYAGER). Am J Cardiol 105 : 69-76, 2010.
  pubmed

• 6) Mabuchi H, et al : Therapy : PCSK9 inhibitors for treating familial hypercholesterolaemia. Nat Rev Endocrinol 11 : 8-9, 2015.
  pubmed

• 7) Robinson J G, et al : Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia : the LAPLACE-2 randomized clinical trial. JAMA 311 : 1870-1882, 2014.

• 8) Myocardial Infarction Genetics Consortium Investigators, et al : Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 371 : 2072-2082, 2014.

• 9) Foody J M, et al : Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113 : 1086-1092, 2006.
  pubmed

• 10) Criner G J, et al : Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 370 : 2201-2210, 2014.
  pubmed

• 11) National Heart, Lung, and Blood Institute ARDS Clinial Trial Network, et al : Rosuvastatin for sepsisassociated acute respiratory distress syndrome. N Engl J Med 370 : 2191-2200, 2014.

• 12) Zhang H, et al : Discontinuation of statins in routine care settings : a cohort study. Ann Intern Med 158 : 526-534, 2013.
  pubmed

• 13) Patrick M Moriarty PDT, et al : Late-breaking clinical trial abstracts : ODYSSEY ALTERNATIVE : Efficacy And Safety of the Proprotein Convertase Subtilisin/kexin Type 9 Monoclonal Antibody, Alirocumab, versus Ezetimibe, in Patients With Statin Intolerance as Defined by a Placebo Run-in and Statin Rechallenge Arm. Circulation 130(suppl 2) : 2105-2126, 2014.

• 14) Sattar N, et al : Statins and risk of incident diabetes : a collaborative meta-analysis of randomised statin trials. Lancet 375 : 735-742, 2010.
  pubmed

• 15) Swerdlow D I, et al : HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight : evidence from genetic analysis and randomised trials. Lancet, 2014. [Epub ahead of print]

P.170 掲載の参考文献

• 1) Chang T Y, et al : Ezetimibe blocks internalization of the NPC1L1/cholesterol complex. Cell metabolism 7(6) : 469-471, 2008.
  pubmed

• 2) 山下静也 : 臨床栄養 vol.111 No2 2007.

• 3) Davis H R Jr, et al : Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Throm Vasc Biol 21(12) : 2032-2038, 2001.

• 4) Davis H R Jr, et al : The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Metabolism 50(10) : 1234-1241, 2001.
  pubmed

• 5) Altmann S W, et al : Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303(5661) : 1201-1204, 2004.
  pubmed

• 6) Garcia-Calvo M, et al : The target of ezetimibe is Niemann-Pick C1-Like 1(NPC1L1). Proceedings National Academy Sciences USA 102(23) : 8132-8137, 2005.

• 7) Pearson T A, et al : A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients : the ezetimibe add-on to statin for effectiveness(EASE) trial. Mayo Clinic Proc 80(5) : 587-595, 2005.

• 8) Brown G, et al : Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323(19) : 1289-1298, 1990.

• 9) Ballantyne C M. et al : Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia : a prospective, randomized, double-blind trial. Circulation 107(19) : 2409-2415, 2003.

• 10) Mohammadi A, et al : Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells. Arterioscler Thromb Vasc Biol 18(5) : 783-793, 1998.
  pubmed

• 11) Strandberg T E, et al : Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly : a prospective study. J Am Coll Cardiol 48(4) : 708-714, 2006.
  pubmed

• 12) Gylling H, et al : Cholesterol absorption and lipoprotein metabolism in type II diabetes mellitus with and without coronary artery disease. Atherosclerosis 126(2) : 325-332, 1996.
  pubmed

• 13) Chirinos J A, et al : Efficacy of cholesterol uptake inhibition added to statin therapy among subjects following a low-carbohydrate diet : a randomized controlled trial. Am Heart J 159(5) : 918. e1-6, 2010.

P.179 掲載の参考文献

• 1) Fruchart J C, et al : The Residual Risk Reduction Initiative : a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res 5 : 319-335, 2008.

• 2) Sarwar N, et al : Triglycerides and the risk of coronary heart disease : 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circuration 15 : 450-458, 2007.

• 3) 日本動脈硬化学会 : 動脈硬化性疾患予防ガイドライン2012年版. 2012.

• 4) Staels B, et al : Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circuration 98 : 2088-2093, 1998.

• 5) Inaba T, et al : Cholesterol reduction and atherosclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice. Hypertens Res 31 : 999-1005, 2008.
  pubmed

• 6) Rubins H B, et al : Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 : 410-418, 1999.

• 7) DAIS investigators : Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes : the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357 : 905-910, 2001.

• 8) Keech A, et al : Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus(the FIELD study) : randomised controlled trial. Lancet 366 : 1849-1861, 2005.

• 9) Accord study group : Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362 : 1563-1574, 2010.

• 10) BIP study investigators : Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease : the Bezafibrate Infarction Prevention (BIP) study. Circulation 102 : 21-27, 2000.

• 11) Jun M, et al : Effects of fibrates on cardiovascular outcomes : a systematic review and meta-analysis. Lancet 375 : 1875-1884, 2010.
  pubmed

• 12) 伊藤善規, 他 : 脂質低化剤による肝障害および筋障害について. TDM研究23 : 32-39, 2006.

• 13) Chawla A, et al : A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7 : 161-171, 2001.
  pubmed

• 14) Chen Z, et al : Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice : pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 21 : 372-377, 2001.
  pubmed

• 15) Dormandy J A, et al : Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomised controlled trial. Lancet 366 : 1279-1289, 2005.
  pubmed

• 16) Mazzone T, et al : Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes : a randomized trial. JAMA 296 : 2572-2581, 2006.
  pubmed

• 17) Kawamori R. et al : Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus : postmarketing surveillance study in Japan. Diabetes Res Clin Pract 76 : 229-235, 2007.
  pubmed

• 18) Linz P E, et al : Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes : the ACCORD Lipid Trial. Diabetes Care 37 : 686-693, 2014.
  pubmed

• 19) Senba H, et al : Severe Decrease in Serum HDL-Cholesterol During Combination Therapy of Bezafibrate and Pioglitazone. J Athero Thrombo 13 : 263-264, 2006.

P.186 掲載の参考文献

• 1) Yamamoto A, et al : Effects of probucol on homozygous cases of familial hypercholesterolemia. Atherosclerosis 48(2) : 157-164, 1983.
  pubmed

• 2) Kita T, et al : Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipiderlic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 84(16) : 5928-5931, 1987.
  pubmed

• 3) Yoshikawa T, et al : Effects of probucol on atherosclerosis of apoE-deficient or LDL receptor-deficient mice. Horm Metab Res 33(8) : 472-479, 2001.
  pubmed

• 4) Tardif J-C, et al : Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 337(6) : 365-372, 1997.
  pubmed

• 5) Yokoi H, et al : Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty : The Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol 30(4) : 855-862, 1997.

• 6) Sasayama Y, et al : Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. J Am Coll Cardiol 39(4) : 610-616, 2002.

• 7) Walldius G, et al : The effect of probucol in femoral atherosclerosis : The Probucol Quantitative Regression Swedish Trial(PQRST). Am J Cardiol 74(9) : 875-883, 1994.
  pubmed

• 8) Yamashita S, et al : Long-term probucol treatment prevents cardiovascular events : a cohort study of patients with heterozygous familial hypercholesterolemia. J Atheroscler Thromb 15(6) : 292-303, 2008
  pubmed

• 9) Endo K, et al : Probucol delays progression of diabetic nephropathy. Diabetes Res Clin Pract 71(2) : 156-163, 2006.
  pubmed

• 10) Endo K, et al : Probucol suppresses initiation of chronic hemodialysis thrapy and renal dysfunction-related death in diabetic nephropathy patients : Sakura study. J Atheroscler Thromb 20(5) : 494-502, 2013.

• 11) Kume N, et al : Induction of mRNA for low-density lipoprotein receptors in heterozygous Watanabe heritable hyperlipidemic rabbits treated with CS-514(Pravastatin) and cholestyramine. Circulation 79(5) : 1084-1090, 1989.
  pubmed

• 12) The Lipid Research Clinics Coronary Primary Prevention Trial results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251(3) : 365-374, 1984.
  pubmed

• 13) Neda T, et al : Hypoglycemic effects of colestimide on type 2 diabetic patients with obesity. Endocr J 59(3) : 239-246, 2012.
  pubmed

P.194 掲載の参考文献

• 1) 脂質異常症-動脈硬化性疾患予防のために. 診断と治療 100(12) : 2046, 2012.

• 2) Dyerberg J, et al : A hypothesis on the development of acute myocardial infarction in Greenlanders. Scand J Clin Lab Invest suppl 161 : 7-13, 1982.
  pubmed

• 3) Bang H O, et al : The composition of the Eskimo food in north western Greenland. Am J Clin Nutr 33(12) : 2657-2661, 1980.
  pubmed

• 4) He K, et al : Accumulated evidence on fish consumption and coronary heart disease mortality : a meta-analysis of cohort studies. Circulation 109(22) : 2705-2711, 2004.
  pubmed

• 5) Dyerberg J, et al : Ercosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet 312(8081) : 117-119, 1978.

• 6) Yokoyama M, et al : Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients(JELIS) : a randomised open-label, blinded endpoint analysis. Lancet 369(9567) : 1090-1098, 2007.
  pubmed

• 7) Cole G M, et al : DHA may prevent age-related dementia. J Nutr 140(4) : 869-874, 2010.
  pubmed

• 8) Mozaffarian D : JELIS, fish oil, and cardiac events. Lancet 369 : 1062-1063, 2007.
  pubmed

• 9) Jump D B : The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 277(11) : 8755-8758, 2002.

• 10) Khan S, et al : Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype. J Lipid Res 43(6) : 979-985, 2002.
  pubmed

• 11) Yahagi N, et al : A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids. J Biol Chem 274(50) : 35840-35844, 1999.
  pubmed

• 12) Takeuchi Y, et al : Polyunsaturated fatty acids selectively suppress sterol regulatory element-binding protein-1 through proteolytic processing and autoloop regulatory circuit. J Biol Chem 285(15) : 11681-11691, 2010.
  pubmed

• 13) Satoh N, et al : Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care 30(1) : 144-146, 2007.

• 14) 寺野 隆, 他 : EPA-E 投与によるラット白血球 LTB4産生の変化. 炎症11(5) : 467-472, 1991.

• 15) Wise A, et al : Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 278(11) : 9869-9874, 2003.
  pubmed

• 16) Offermanns S : The nicotinic acid receptor GPR109A(HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol Sci 27 : 384-390, 2006.

• 17) Zhang L H, et al : Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells. J Lipid Res 53(5) : 941-950, 2012.
  pubmed

• 18) Taylor A J, et al : Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2 : a double-blind, place-bo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110(23) : 3512-3517, 2004.

• 19) HPS2-THRIVE Collaborative Group, et al : Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371(3) : 203-212, 2014.

• 20) Svedmyr N, et al : Influence of indomethacin on flush induced by nicotinic acid in man. Acta Pharmacol Toxicol(Copenh) 41(4) : 397-400, 1977.
  pubmed

• 21) Benyo Z, et al : Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol Pharmacol 70(6) : 1844-1849, 2006.
  pubmed

P.203 掲載の参考文献

• 1) Kikkawa T, et al : Specifity of various plasmapheresis techniques for treatment of hypercholesterolemia. In : Current Practice in Therapeutic Plasmapheresis (Shiokawa Y, et al, eds), pp145-151. Excerpta Medica, 1985.

• 2) Yokoyama S, et al : Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis. Characterization and experimental use in hypercholesterolemic rabbits. Arteriosclerosis 4 : 276-282, 1984.
  pubmed

• 3) Goldstein J L, et al : The Metabolic Basis of Inherited Disease 5th ed. macGraw-Hill, New York, 1982.

• 4) Tamai O, et al : Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 95 : 76-82, 1997.
  pubmed

• 5) Yuasa Y, et al : Proteomic analysls of proteins eliminated by LDL-apheresis. Ther Apher Dial(in press)

• 6) Makino H, et al : Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia. Ther Apher Dial 7 : 397-401, 2003.
  pubmed

• 7) Hori M, et al : Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9(pcsk9) by low-density lipoprotein-apheresis in familial hypercholesterolemia : Development and application of a new assay for pcsk9. J Clin Endocrinol Metab 2014. (in press)

• 8) Tsurumi-Ikeya Y, et al : Sustained inhibition of oxidized low-density lipoprotein is involved in the long-term therapeutic effects of apheresis in dialysis patients. Arterioscler Thromb Vasc Biol 30 : 1058-1065, 2010.

• 9) Kroon A A, et al : LDL-apheresis atherosclerosis regression study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 93 : 1826-1835, 1996.
  pubmed

• 10) Grasdal A, et al : Apheresis in homozygous familial hypercholesterolemia : The results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J Clin Lipidol 6 : 331-339, 2012.

• 11) Mabuchi H, et al : Long-term efficacy of low density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 82 : 1495-1489, 1998.

• 12) Sampietro T, et al : Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia. Circulation 96 : 1281-1385, 1997.

• 13) Kobayashi S, et al : LDL-apheresis reduces P-Selectin, CRP and fibrinogen-possible important implications for improving atherosclerosis. Ther Apher Dial 10 : 219-223, 2006.
  pubmed

• 14) Roth E M, et al : Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 15 : 367 : 1891-1900, 2012.

• 15) Cuchel M, et al : Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia : a single-arm, open-label, phase 3 study. Lancet 381 : 40-46, 2013.
  pubmed

P.210 掲載の参考文献

• 1) Stone N J, et al : 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 : 2889-2934, 2014.

• 2) Ridker P M : LDL cholesterol : controversies and future therapeutic directions. Lancet 384 : 607-617, 2014.
  pubmed

• 3) 日本動脈硬化学会 : 動脈硬化性疾患予防ガイドライン2012. 協和企画, 東京, 2012.

• 4) Nissen S E, et al : REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis : a randomized controlled trial. JAMA 291 : 1071-1080, 2004.

• 5) Nissen S E, et al : Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 : 29-38, 2005.
  pubmed

• 6) Nissen S E, et al : Effect of very high-intensity statin therapy on regression of coronary atherosclerosis : the ASTEROID trial. JAMA 295 : 1556-1565, 2006.

• 7) Nicholls S J, et al : Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 : 499-508, 2007.
  pubmed

• 8) Barter P, et al : Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol. and cardiovascular events. N Engl J Med 357 : 1301-1310, 2007.
  pubmed

• 9) deGoma E M, et al : Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholestcrol. Am Coll Cardiol 51 : 49-55, 2008.
  pubmed

• 10) Okazaki S, et al : Early statin treatment in patients with acute coronary syndrome : demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event : the ESTABLISH Study. Circulation 110 : 1061-1068, 2004.
  pubmed

• 11) Blazing M A, et al : Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes : final baseline characteristics of the IMPROVE-IT study population. Am Heart J 168 : 205-212, 2014.
  pubmed

• 12) Daida H, et al : Justification for Atherosclerosis Regression Treatment(JART) Investigators. J Atheroscler Thromb 21 : 739-754, 2014.
  pubmed

P.223 掲載の参考文献

• 1) Matsuzawa Y, et al : Marked hyper-HDL2-cholesterolemia associated with premature corneal opacity. A case report. Atherosclerosis 53 : 207-212, 1984.
  pubmed

• 2) Ishigami M, et al : Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein(CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J Biochem 116 : 257-262, 1994.

• 3) Ansell B J, et al : High-density lipoprotein function recent advances. J Am Coll Cardiol 46 : 1792-1798, 2005.
  pubmed

• 4) Yamashita S, et al : Small polydisperse low density lipoproteins in familial hyperalphalipoproteinemia with complete deficiency of cholesteryl ester transfer activity. Atherosclerosis 70 : 7-12, 1988.
  pubmed

• 5) Sakai N, et al : Decreased affinity of low density lipoprotein(LDL) particles for LDL receptors in patients with cholesteryl ester transfer protein deficiency. Eur J Clin Invest 25 : 332-339, 1995.
  pubmed

• 6) Yamashita S, et al : Accumulation of apolipoprotein E-rich high density lipoproteins in hyperal-phalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency.J Clin Invest 86 : 688-695, 1990.

• 7) Hirano K, et al : Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperal-phalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 17 : 1053-1059, 1997.

• 8) Yamashita S, et al : Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia. Atherosclerosis 152 : 271-285, 2000.
  pubmed

• 9) Hirano K, et al : Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vasc Biol 15 : 1849-1856, 1995.
  pubmed

• 10) Zhong S, et al : Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 97 : 2917-2923, 1996.

• 11) Thompson A, et al : Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 299 : 2777-2788, 2008.
  pubmed

• 12) Vasan R S, et al : Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 120 : 2414-2420, 2009.
  pubmed

• 13) Robins S J, et al : Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study. Atherosclerosis 228 : 230-236, 2013.
  pubmed

• 14) Ritsch A, et al : Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography : the Ludwigshafen Risk and Cardiovascular Health study. Circulation 121 : 366-374, 2010.
  pubmed

• 15) Duwensee K, et al : Cholesteryl ester transfer protein in patients with coronary heart disease. Eur J Clin Invest 40 : 616-622, 2010.
  pubmed

• 16) van Acker B A, et al : High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants. Atherosclerosis 200 : 161-167, 2008.

• 17) Schierer A, et al : Genetic variation in cholesterol ester transfer protein, serum CETP activity, and coronary artery disease risk in Asian Indian diabetic cohort. Pharmacogenet Genomics 22 : 95-104, 2012.
  pubmed

• 18) Miller N E : CETP inhibitors and cardiovascular disease : Time to think again. F1000Res 3 : 124, 2014.
  pubmed

• 19) Barter P J, et al : Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 : 2109-2122, 2007.
  pubmed

• 20) Nissen S E, et al : Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 : 1304-1316, 2007.
  pubmed

• 21) Kastelein J J, et al : Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356 : 1620-1630, 2007.
  pubmed

• 22) Bots M L, et al : Torcetrapib and carotid intimamedia thickness in mixed dyslipidaemia(RADIANCE 2 study) : a randomised, double-blind trial. Lancet 370 : 153-160, 2007.
  pubmed

• 23) Schwartz G G, et al : Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367 : 2089-2099, 2012.
  pubmed

• 24) Khera A V, et al : Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364 : 127-135, 2011.
  pubmed

• 25) Rohatgi A, et al : HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014 [Epub ahead of print]

• 26) Cannon C P, et al : Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 363 : 2406-2415, 2010.

• 27) Cannon C P : High-density lipoprotein cholesterol as the Holy Grail. JAMA 306 : 2153-2155, 2011.
  pubmed

• 28) Nicholls S J, et al : Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol : a randomized controlled trial. JAMA 306 : 2029-2109, 2011.
  pubmed

• 29) Keene D, et al : Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors : meta-analysis of randomised controlled trials including 117,411 patients. BMJ 349 : g4379, 2014.
  pubmed

• 30) Matsuzawa Y, et al : Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. Am J Cardiol 62 : 66B-72B, 1988.
  pubmed

• 31) Matsuzawa Y, et al : Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. Am J Cardiol 62 : 66B-72B, 1988.
  pubmed

• 32) Ishigami M, et al : High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Eur J Clin Invest 27 : 285-292, 1997.
  pubmed

• 33) Hirano K, et al : Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism. Arterioscler Thromb Vasc Biol 25 : 2422-2427, 2005.

• 34) Yamashita S, et al : Long-term probucol treatment prevents secondary cardiovascular events : a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb 15 : 292-303, 2008.
  pubmed

• 35) Kasai T, et al : Probucol therapy improves long-term(>10-year) survival after complete revascularization : a propensity analysis. Atherosclerosis 220 : 463-469, 2012.
  pubmed